Targeting a key factor in pancreatic cancer treatment resistance
Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma
This study is looking at a tough type of pancreatic cancer and testing a new approach to make current treatments work better by blocking a specific protein, which could help improve outcomes for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11009521 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDA), a highly aggressive cancer with low survival rates. It investigates the role of HNF1A, a transcription factor that contributes to the resistance of pancreatic cancer stem cells to therapies. By using BET-inhibitors to block HNF1A, the research aims to enhance the effectiveness of existing treatments targeting KRAS and its pathways. Patients may benefit from new therapeutic strategies that could improve treatment outcomes for this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those who have shown resistance to current therapies.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, indicating that this approach may lead to significant advancements.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Abel, Ethan Vincent — Roswell Park Cancer Institute Corp
- Study coordinator: Abel, Ethan Vincent
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.